What is Medmo?
Medmo operates at the intersection of healthcare technology and administrative optimization. The company addresses the persistent challenges within the medical imaging market, where patients frequently encounter barriers such as excessive wait times, geographic limitations, and opaque pricing structures. By providing a sophisticated platform that simplifies the imaging process, Medmo empowers patients to make informed decisions while simultaneously reducing the administrative burden on imaging centers and ordering physicians.
Beyond patient-facing solutions, the company focuses on driving capacity management efficiencies. By improving patient adherence and optimizing workflow, Medmo acts as a critical infrastructure layer that enhances the overall quality of care. Its market position is defined by its dual-sided value proposition: improving the patient experience while providing the necessary tools for providers to manage their resources more effectively in an increasingly complex regulatory and clinical environment.
How much funding has Medmo raised?
Medmo has raised a total of $38.6M across 3 funding rounds:
Other Financing Round
$9M
Private Equity
$14.6M
Series A
$15M
Other Financing Round (2023): $9M with participation from C2 Ventures, Jerusalem Venture Partners, and Lerer Hippeau Ventures
Series A (2025): $15M led by Covera Health, Origin Ventures, Lerer Hippeau Ventures, and Toppan Global Venture Partners
Private Equity (2025): $14.6M, investors not publicly disclosed
Key Investors in Medmo
Covera Health
Covera Health is a leading clinical analytics company that pioneers solutions for clients and providers to reduce the high costs associated with medical misdiagnoses.
Origin Ventures
Origin Ventures is an early-stage venture capital firm that invests in bold founders and innovative companies transforming productivity and automation through artificial intelligence.
Lerer Hippeau Ventures
Lerer Hippeau is a venture capital firm focused on investing in innovative startups, particularly in the early stages, supporting founders who tackle challenging problems across enterprise and consumer landscapes.
What's next for Medmo?
With the successful closure of this major strategic investment, Medmo is poised to enter a phase of aggressive scaling. The company's roadmap likely involves expanding its network of imaging providers and deepening its integration with clinical analytics platforms to further reduce the incidence of medical misdiagnoses. As the firm transitions into a more mature enterprise-level entity, the focus will shift toward enhancing its proprietary software capabilities and potentially exploring new market segments within the broader healthtech ecosystem.
The involvement of seasoned investors suggests a long-term commitment to transforming the diagnostic imaging value chain. Moving forward, Medmo will likely prioritize the deployment of its capital toward product innovation and market penetration, aiming to set a new standard for transparency and operational excellence in the healthcare sector.
